权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A rapid response detector for intensity modulated proton therapy dosimetry

用于调强质子治疗剂量测定的快速响应探测器

基本信息

批准号：
8312118
负责人：
Keith A Solberg
金额：
$ 20.59万
依托单位：
PROCURE TREATMENT CENTERS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-09-08 至 2013-07-07
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8312118
关键词：
Adverse effects Argon Capital Clinical Contracts Coupled Custom Cyclotrons Detection Dose Dose-Rate Electronics Engineering Environment Equipment Failure Feedback Frequencies Gases Genetic Recombination Goals Hospitals Indiana Institutes Ions Light Mainstreaming Marketing Massachusetts Measurement Measures Methods Michigan Modality Monitor Output Patients Phase Physiologic pulse Positioning Attribute Proton Radiation Protons Radiation Radiation therapy Radioactive Reporting Research Resolution Rivers Safety Scanning Scheme Small Business Innovation Research Grant Source Spottings Synchrocyclotron System Techniques Technology Testing Time Tube Tumor Volume Universities Work Writing Xenon base cancer therapy clinical practice cost data acquisition design detector dosimetry imaging detector innovation instrument interest ionization novel operation photomultiplier proton beam prototype response tumor

项目摘要

DESCRIPTION (provided by applicant): In recent years there has been increased interest throughout the world in the use of proton radiation therapy for treatment of cancer. Currently, there are only 9 operational centers in the US that treat a total of about 7,000 patients per year comprising less than 1% of all patients that receive radiation therapy. However, at least 30% of patients would benefit from treatment with proton beams. The capital and operating cost of extant systems is a major limiting factor. One attractive option being developed by at least two commercial suppliers is based on compact high field superconducting synchrocyclotron (SCSC) technology developed at MIT. The SCSC has many attractive features such as cost, size and ease of operation. However, it has one potential major drawback due to the very low duty cycle whereby beam pulses of about 10 ns in duration occur about 1000 times per second. Real-time detectors currently in clinical practice have several deficiencies for utilization with short pulse beams such as delivered by a SCSC, A detector that can measure these small, short duration, beam spots in real-time and provide feedback is required. The overall goal for this SBIR project is to perform the research needed to develop an innovative detector that would be suitable for the above application. ProCure proposes a novel technique that takes advantage of the very short proton SCSC pulse to measure only the fast scintillation light from direct atomic excitations in Zenon within a narrow time gate of about 100ns following the proton pulse thus avoiding the problem of ion recombination that occur over a much longer time scale. We emphasize that this scheme, based on fast emitted light detection and fast electronics, will achieve linear response and no saturation when used with intense sub-microsecond beam pulses. In Phase I, the research team will concentrate on developing a working prototype detector and measuring its parameters. Based on the results of these studies in Phase II ProCure will focus on the engineering and construction of full-scale 30¿30 cm2 detectors as well as design of custom data acquisition electronics. This will be followed by the comprehensive testing required for FDA 510k approval, leading to a final marketable product. PUBLIC HEALTH RELEVANCE: Proton therapy provides the best possible option for using radiation to control and eliminate tumors with the least short and long term toxic side effects but its utilization is restricted by the size and cost of extant equipment. One attractive option being commercialized is based on compact high field superconducting synchrocyclotrons (SCSC) technology. However existing detectors used in clinical practice are not capable of monitoring the dose from such a machine and the novel detector proposes here by ProCure is required to do so and consequently help to bring this highly effective form of cancer treatment to the mainstream of radiation therapy in a more affordable option.

描述（由申请人提供）：近年来，全世界对使用质子放射疗法治疗癌症的兴趣越来越大。目前，美国只有9个手术中心，每年治疗约7,000名患者，占所有接受放射治疗患者的不到1%。然而，至少30%的患者将受益于质子束治疗。现存系统的资本和运营成本是一个主要的限制因素。至少有两家商业供应商正在开发的一种有吸引力的选择是基于麻省理工学院开发的紧凑型高场超导同步回旋加速器（SCSC）技术。SCSC具有许多吸引人的特点，如成本，尺寸和易于操作。然而，由于占空比非常低，因此它具有一个潜在的主要缺点，其中持续时间约为10 ns的光束脉冲每秒发生约1000次。目前在临床实践中的实时检测器对于短脉冲的使用具有几个缺陷需要能够实时测量这些小的、短持续时间的束斑并提供反馈的检测器。该SBIR项目的总体目标是进行开发适合上述应用的创新探测器所需的研究。ProCure提出了一种新的技术，该技术利用非常短的质子SCSC脉冲来测量直接原子激发的快速闪烁光在Zenon中，在质子脉冲之后约100 ns的窄时间门内，从而避免了在长得多的时间尺度上发生的离子复合的问题。我们强调，这种方案，基于快速发射光检测和快速电子学，将实现线性响应，没有饱和时，使用强烈的亚微秒光束脉冲。在第一阶段，研究小组将集中精力开发一个工作原型探测器并测量其参数。根据这些研究的结果，在第二阶段，ProCure将专注于全尺寸30 - 30 cm 2探测器的工程和建设以及定制数据采集电子设备的设计。随后将进行FDA 510 k批准所需的全面测试，从而获得最终可销售的产品。公共卫生关系：质子治疗提供了使用放射来控制和消除肿瘤的最佳选择，具有最小的短期和长期毒副作用，其利用受到现存设备的尺寸和成本的限制。一个有吸引力的选择是商业化的超导同步回旋加速器基于紧凑型高场超导同步回旋加速器（SCSC）技术。然而，临床实践中使用的现有探测器无法监测来自这种机器的剂量，并且需要ProCure在此提出的新型探测器来这样做，从而有助于将这种高效的癌症治疗形式以更实惠的选择带入放射治疗的主流。